29.26

4.19% -1.2215

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $29.26, with a volume of 689.13K. It is down -4.19% in the last 24 hours and up +11.08% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Previous Close:

$30.48

Open:

$29.527

24h Volume:

689.13K

Relative Volume:

0.32

Market Cap:

$3.03B

Revenue:

$164.01M

Net Income/Loss:

$-65.04M

P/E Ratio:

-42.59

EPS:

-0.687

Net Cash Flow:

$-383.84M

1W Performance:

-1.87%

1M Performance:

+11.08%

6M Performance:

+2.61%

1Y Performance:

+73.31%

1-Day Range:

$29.01

$30.50

1-Week Range:

$28.23

$31.48

52-Week Range:

$16.02

$38.26

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1088)

Industry

Biotechnology (605)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

522

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	29.30	2.93B	164.01M	-65.04M	-383.84M	-0.687
VRTX Vertex Pharmaceuticals Inc	542.74	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	791.06	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,029.48	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.61	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	206.72	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-20-26	Initiated	Canaccord Genuity	Buy
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

Aug 20, 2026

Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2%Here's What Happened - MarketBeat

Aug 20, 2026

Beam (BEAM) Range: Posts a 1.62% Loss to $28.60 on the Day; Current Setup: $27.17 and $30.03 Define the Nearby Reference Levels in the Available RecordDebt Free Companies - Vinanet

Aug 20, 2026

Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters

Aug 20, 2026

Aug 19, 2026

Beam (BEAM) Latest Quarter: EPS Falls Short of Its Estimate on the Day; Post-Earnings: The Stock Gains 9.41% in the Current UpdateRevenue Inflection Point - Vinanet

Aug 19, 2026

Beam (BEAM) Today: Adds 6.91% to Close at $28.41 on the Day; Range Check: Price Remains Between $26.99 Support and $29.83 Resistance in the Available RecordRVOL Spike - Vinanet

Aug 19, 2026

Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpShould You Buy? - MarketBeat

Aug 19, 2026

Aug 18, 2026

Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM - MarketBeat

Aug 18, 2026

Aug 17, 2026

Beam Therapeutics (BEAM) Edges Higher as Gene Editing Sector Draws Fresh AttentionCash Secured Put - Vinanet

Aug 17, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 17, 2026

Aug 16, 2026

Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat

Aug 16, 2026

Aug 14, 2026

Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position - Stock Titan

Aug 13, 2026

Aug 11, 2026

Equities Analysts Offer Predictions for BEAM Q3 Earnings - MarketBeat

Aug 11, 2026